Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 697Urinary Bladder Neoplasms 256Carcinoma, Renal Cell 190Kidney Neoplasms 94Neoplasms 72Carcinoma, Transitional Cell 69Breast Neoplasms 66Lung Neoplasms 38Ovarian Neoplasms 37Melanoma 37Colorectal Neoplasms 37Stomach Neoplasms 36Non-Muscle Invasive Bladder Neoplasms 35Neoplasm Metastasis 33Pancreatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 29Recurrence 26Colonic Neoplasms 25Uterine Cervical Neoplasms 20Urologic Neoplasms 20Testicular Neoplasms 20Esophageal Neoplasms 20Liver Neoplasms 18Head and Neck Neoplasms 18Disease 18Wilms Tumor 17Carcinoma, Hepatocellular 17Endometrial Neoplasms 16Sarcoma 15Prostatic Hyperplasia 15

Interventions

proxalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoadjuvant Therapy \High Risk Prostate Cancer × Genitourinary × Clear all
NCT05076851 2021-10-13

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
2 enrolled
Genitourinary

Neoadjuvant Therapy \High Risk Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡